Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ANDROMEDA: AZD9750 in Metastatic Prostate Cancer
NCT07336446Phase 2Active, not recruiting
- Sponsor
- AstraZeneca
- Start
- Jan 2026
- Primary completion
- Nov 2026
- Modality
- Bivalent/Multivalent Binders, PROTACs (E3 ligase recruitment)
- Countries
- 4
01
Overview
A Phase 2 trial of AZD9750 in prostate cancer (PCa), sponsored by AstraZeneca. Started Jan 2026; status: active, not recruiting.
02
Drugs
AZD9750
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07336446.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07336446.